15 Jun PRESS RELEASE: Atomo wins funding for new rapid blood test to help detect heart attack
SYDNEY, Australia, 15 June 2016 | Australian medical device innovator, Atomo Diagnostics today announced it has been selected as a winner of the Advance Queensland Johnson & Johnson Innovation QuickFire Challenge. The win was announced by the Premier of Queensland, Annastacia Palaszczuk, at the QUT Institute of Health & Biomedical Innovation.
Atomo received the award in the medical device sector of the challenge, which comes with $100,000 in funding to deliver a ‘proof of concept’ program for an innovative rapid test to detect heart attack.
Atomo Diagnostics Group CEO John Kelly said, “We gratefully thank the Queensland Government and Johnson & Johnson Innovation for their support. This funding will allow us to evaluate the feasibility of an easy-to-use test for the early detection of heart attacks away from laboratory and hospital settings.”
Sydney-based Atomo Diagnostics will partner with Brisbane-based Anteo Technologies to develop a clinical prototype of a cost effective and accurate point of care test for the diagnosis of heart attacks.
Anteo Group CEO Jef Vangenechten said, “Anteo’s novel binding chemistry is particularly well suited to advancing performance improvements of point of care tests. We are pleased to partner with a fellow innovator of the Australian medical device sector, to develop a next generation troponin test on the AtomoRapid platform.”
Anteo will develop a rapid test strip for cardiac troponin using its coating technology which has been previously shown to improve the performance of immunoassay tests. Atomo will then integrate this into its award-winning AtomoRapid platform which provides unparalleled ease of use and robustness in point of care settings.
The troponin test market is one of the largest and fastest growing single cardiac biomarkers segments 1 and the point of care (non-laboratory) market is estimated to be US$350 million per annum2. Subject to a successful proof of concept phase, Atomo and Anteo will consider options to fully commercialise an AtomoRapid based troponin solution for the cardiac market.
Tim Allerton or Andrew Geddes
Tel: +61 (2) 9267 4511
Tel: +61 (7) 3219 0085
1. Cardiac Marker Diagnostic Testing Markets, TriMark Publications, Volume: TMRCMARK15-0701, July 2015
2. Trinity Biotech Announces European Approval of Guideline Compliant, Point-of-Care, High Sensitivity Troponin I Product, accessed November 2015